---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-22-008514"
form_type: "8-K"
ticker: null
cik: "0001629205"
company_name: "Innovation1 Biotech Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:25:33.492056+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Innovation1 Biotech sells Mioxal® assets to Ingenius Biotech for stock and royalties

## Summary
- Company transferred all Mioxal-related assets including IP to Ingenius Biotech S.L.
- Consideration includes 350,000 shares of Innovation1 common stock to Ingenius.
- Ingenius to pay $100,000 upon first sale/commercialization and a 5% royalty on net sales.
- Ingenius releases Innovation1 from all Mioxal liabilities and provides indemnification.
- Transaction completed on November 7, 2022.

## SEC filing metadata
- accession: 0001477932-22-008514
- form_type: 8-K
- cik: 0001629205
- company_name: Innovation1 Biotech Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/0001477932-22-008514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/ivbt_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-22-008514
- JSON: https://secwatch.observer/filing/0001477932-22-008514.json
- Plain text: https://secwatch.observer/filing/0001477932-22-008514.txt

## Key facts
- M&A Transactions
  Innovation1 Biotech Inc. completed a disposition involving Ingenius Biotech S.L. (closed 2022-11-07).
  - Action: disposition
  - Counterparty: Ingenius Biotech S.L.
  - Closing: 2022-11-07
  source text: On November 7, 2022, Innovation1 Biotech Inc., a Nevada corporation (the “Company”), completed the disposition (the “Disposition”) of all of the assets, including intellectual property assets, relating to Mioxal®, a nutraceutical complex composed of essential amino acids, natural coenzymes and minerals, to Ingenius Biotech S.L., a corporation organized under the laws of Spain (“Ingenius”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/0001477932-22-008514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.